Condition: Advanced Non-small Cell Lung Cancer, HER2 Mutation · Sponsor: Bayer
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC is a group of lung cancers that have spread to nearby tissues or to other parts of the body or that are unlikely to be cured or controlled with currently available treatments. HER2 is a protein that helps cells to grow and divide. A damage (also called mutation) to the building plans (genes) for this protein in cancer cells leads to a production of abnormal HER2 and therefore abnormal cell growth and division. The study treatment, sevabertinib, is expected to block the mutated HER2 protein which may stop the spread of NSCLC. The main purpose of this study is to learn how well sevabertinib works and how safe it is compared with standard treatment, in participants who have advanced NSCLC with specific genetic changes called HER2 mutations. The study participants will receive one of the study treatments: * Sevabertinib twice every day as a tablet by mouth, or * Standard treatment in cycles of 21 days via infusion ("drip") into the vein. * Participants will continue their assigned treatment for as long as they benefit from it and do not experience severe side effects, or until they or their doctor decide to stop treatment. When a participant receiving the standard treatment has their disease get worse (this is called "disease progression"), they may have the…
This description comes directly from the study's public registry record.
Bayer Clinical Trials Contact · (+)1-888-84 22937 · clinical-trials-contact@bayer.com
Always discuss trial participation with your own doctor first.
| Patty & George Hoag Cancer Center | Newport Beach, California, United States | Withdrawn |
| UC San Diego Health - Moores Cancer Center | San Diego, California, United States | Recruiting |
| UCSF Bakar Precision Cancer Medicine Building - Thoracic Surgery and Oncology | San Francisco, California, United States | Recruiting |
| UCLA Health Santa Monica Cancer Care | Santa Monica, California, United States | Recruiting |
| The Oncology Institute of Hope and Innovation - Fort Lauderdale 17th Street | Fort Lauderdale, Florida, United States | Recruiting |
| Memorial Cancer Institute at Miramar | Miramar, Florida, United States | Recruiting |
| AdventHealth Cancer Institute Orlando | Orlando, Florida, United States | Recruiting |
| Moffitt Cancer Center - Magnolia Campus | Tampa, Florida, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Not Yet Recruiting |
| Piedmont Healthcare - Atlanta | Atlanta, Georgia, United States | Recruiting |
| John B. Amos Cancer Center | Columbus, Georgia, United States | Recruiting |
| University of Illinois Hospital - Outpatient Cancer Care Center | Chicago, Illinois, United States | Recruiting |
+ 273 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06452277